- Report
- April 2025
- 200 Pages
Global
From €3932EUR$4,490USD£3,413GBP
- Report
- February 2025
- 200 Pages
Global
From €3932EUR$4,490USD£3,413GBP
- Report
- January 2026
- 180 Pages
Global
From €3941EUR$4,500USD£3,421GBP
- Report
- August 2020
- 250 Pages
Saudi Arabia
From €2049EUR$2,340USD£1,779GBP
€3153EUR$3,600USD£2,737GBP
- Report
- September 2024
- 110 Pages
Global
From €5211EUR$5,950USD£4,523GBP
- Report
- March 2024
- 200 Pages
Global
From €3635EUR$4,150USD£3,155GBP
- Report
- May 2024
- 140 Pages
Global
From €3502EUR$3,999USD£3,040GBP
- Drug Pipelines
- February 2019
- 43 Pages
Global
From €8758EUR$10,000USD£7,602GBP
Synjardy is a brand of endocrine and metabolic disorder drugs used to treat type 2 diabetes. It is a combination of empagliflozin and metformin, two drugs that work together to reduce blood sugar levels. Synjardy is taken orally and works by increasing the amount of glucose that is removed from the blood and decreasing the amount of glucose that is produced by the liver. It also helps to reduce the amount of glucose that is absorbed from food. Synjardy is used in combination with diet and exercise to improve glycemic control in adults with type 2 diabetes.
The Synjardy market is highly competitive, with many companies offering similar products. Some of the major players in the market include Boehringer Ingelheim, Merck & Co., Sanofi, Novo Nordisk, and Eli Lilly. Other companies in the market include AstraZeneca, GlaxoSmithKline, and Takeda Pharmaceuticals. Show Less Read more
